Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8104104 | 0.82 | CRBN (0.67) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL21995598 | 0.81 | CRBN (0.71) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL10192194 | 0.80 | MAPT (0.53) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL1421342 | 0.80 | DDB1 (0.46) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL10813665 | 0.80 | MEN1 (0.53) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL4539723 | 0.80 | CRBN (0.46) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL746783 | 0.79 | CRBN (0.66) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL1788429 | 0.78 | MEN1 (0.58) | CRBNDDB1KDM4EGAAMAPT | |
| SCHEMBL11849406 | 0.78 | CRBN (0.63) | CRBNDDB1KDM4EGAAMAPT | |
| Hydrochloric Acid SCHEMBL31439105 | 0.78 | CRBN (0.63) | CRBNDDB1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025236004-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575114-B2 | SGLT-2 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2005023232-A2 | THERAPEUTIC, SCREENING AND DIAGNOSTIC METHODS BASED ON THE EFFECT OF CB1 RECEPTOR MODULATION ON LYMPHOPROLIFERATIVE DISORDERS. | AFFIBODY AB (SE) | 2005-03-17 | — | — | WO | disclosed |
| EP-0444546-B1 | Hydantoin derivatives for use as hypoglycemic and/or hypolipidemic agents | MOCHIDA PHARM CO LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237527-A1 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF | SLC5A2, SLC5A1, SLC10A1 | CRBN 4844/4885DDB1 3019/4885KDM4E 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.